Atara Biotherapeutics, INC Form 4 insider transactions

Redmile Group, LLC and 1 other reported changes in beneficial ownership of Atara Biotherapeutics, Inc. common stock on July 22, 2026.

Atara Biotherapeutics director Brian Cherry was granted 24,000 restricted stock units as part of his compensation package.

Director William K. Heiden received a grant of 12,000 restricted stock units from Atara Biotherapeutics.

Director Matthew K. Fust was granted 12,000 restricted stock units in Atara Biotherapeutics, Inc.

Director Gregory A. Ciongoli was granted 12,000 restricted stock units by Atara Biotherapeutics, Inc.

Atara Biotherapeutics CEO AnhCo Nguyen sold 5,241 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Chief Accounting Officer Yanina Grant-Huerta sold 2,414 shares of Atara Biotherapeutics to cover tax obligations.

Panacea Innovation Ltd and James Huang reported the sale of 313,446 shares of Atara Biotherapeutics, Inc. common stock.

EcoR1 Capital, LLC reported the acquisition of 507,407 shares of Atara Biotherapeutics, Inc. common stock.

Panacea Innovation Ltd., a 10% owner and director of Atara Biotherapeutics, Inc., exercised warrants to acquire 259,163 shares of common stock.

Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold common stock to cover tax obligations related to restricted stock unit vesting.

Atara Biotherapeutics' President and CEO, AnhCo Nguyen, sold 2,996 shares of common stock on March 2, 2026, to cover tax withholding obligations related to restricted stock unit vesting.

A director and 10% owner of Atara Biotherapeutics, Panacea Innovation Ltd, sold 80,554 shares of common stock for approximately $6.07 per share.

Panacea Innovation Ltd, a 10% owner and director, reported the exercise of warrants and acquisition of common stock in Atara Biotherapeutics, Inc.

Atara Biotherapeutics' President and CEO, AnhCo Nguyen, sold 2,915 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold common stock to cover tax obligations related to vested restricted stock units.

Atara Biotherapeutics' President and CEO, AnhCo Nguyen, sold 2,958 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold shares to cover tax withholding obligations related to vested restricted stock units.

A 10% owner and director, Panacea Innovation Ltd, acquired 55,000 shares of Atara Biotherapeutics common stock for approximately $670,422.

Panacea Innovation Ltd and Director James Huang have acquired 19,335 shares of Atara Biotherapeutics, Inc. common stock for approximately $186,300, increasing their indirect beneficial ownership to 1,350,000 shares.

Atara Biotherapeutics, Inc. Director Carol Giltner Gallagher was granted 7,828 restricted stock units (RSUs) on June 10, 2025, bringing her total beneficial ownership to 33,012 shares, adjusted for a recent 1:25 reverse stock split.

Atara Biotherapeutics Director Matthew Fust was granted 7,828 restricted stock units on June 10, 2025, increasing his beneficial ownership to 18,188 shares, following a 1:25 reverse stock split effected in June 2024.

Atara Biotherapeutics, Inc. Director Pascal Touchon was granted 7,828 shares of common stock in the form of restricted stock units on June 10, 2025.

Atara Biotherapeutics Director Maria Grazia Roncarolo reported the acquisition of 7,828 restricted stock units, increasing her beneficial ownership to 17,368 shares, following a recent 1:25 reverse stock split.

Atara Biotherapeutics Director Ameet Mallik was granted 7,828 restricted stock units, which will vest by June 2026 or the next annual meeting, with his total beneficial ownership now reflecting a recent 1:25 reverse stock split.

Atara Biotherapeutics, Inc. Director William K. Heiden was granted 7,828 restricted stock units (RSUs) on June 10, 2025, increasing his beneficial ownership to 22,188 shares.

Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Atara Biotherapeutics' CEO, AnhCo Nguyen, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Adiumentum Capital Fund I LP, along with related entities and Gregory A. Ciongoli, filed a Form 4 detailing changes in their beneficial ownership of Atara Biotherapeutics, Inc. securities, including the acquisition of common stock and warrants.

Former Atara Biotherapeutics executive Eric J. Hyllengren reports the cancellation of employee stock options and a corresponding cash payment.